首版商保创新药目录出炉 多层次医疗保障体系满足患者用药需求

Core Insights - The 2025 Innovation Drug High-Quality Development Conference was held in Guangzhou, where the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and the first Commercial Health Insurance Innovative Drug Catalog were released [1] - The new National Medical Insurance Drug Catalog includes 114 new drugs, of which 50 are Class 1 innovative drugs. The first Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, including CAR-T and treatments for rare diseases like neuroblastoma and Gaucher disease [1] - The National Healthcare Security Administration (NHSA) and the National Health Commission have introduced measures to support the high-quality development of innovative drugs, emphasizing the inclusion of high-innovation, clinically valuable drugs in the commercial health insurance catalog [1] Summary by Sections National Medical Insurance Drug Catalog - The updated catalog adds 114 new drugs, with a significant portion being innovative [1] - The focus is on drugs that provide substantial clinical benefits and are beyond the basic insurance coverage [1] Commercial Health Insurance Innovative Drug Catalog - The catalog includes 19 drugs, highlighting treatments for both common and rare diseases, particularly those affecting children [2] - The catalog aims to bridge the gap between basic medical insurance and commercial insurance, allowing for a wider range of innovative treatments [2] Support for Innovative Drug Development - The NHSA encourages local medical insurance departments to support commercial insurance institutions in designing new products based on the innovative drug catalog [3] - There is a push for a complementary relationship between commercial insurance and basic medical insurance to enhance healthcare coverage for the population [3]